Delivery Order SPE2DB22D9239-SPE2DB25FDK37

Award Date 7/3/25
Potential Completion Date 7/25/25
Potential Value $87K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $87,418.08 and an ultimate completion date of June 27, 2025. The contract covers the delivery of XENPOZYME 20 MG VIALS, a pharmaceutical product, to support the medical supply needs of military health facilities. DMS Pharmaceutical Group Inc....
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $87,418.08, is for the supply of 4567363691 XENPOZYME 20 MG VIALS to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $87,418.08 firm fixed-price contract is for the delivery of XENPOZYME 20 MG VIALS, with a completion date of June 11, 2025. The contract is not set aside for any specific business category. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $109,272.60 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of XENPOZYME 20 MG VIALS and has an ultimate completion date of April 15, 2024. This delivery order is placed under DMS Pharmaceutical Group's existing indefinite delivery contract with DLA, contract 4600082013 under the SPE2DB program, which is valued at up...
This is a delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The contract has a ceiling value of $72,848.30 and is a firm fixed-price delivery order for the pharmaceutical product XENPOZYME 20 MG VIALS. The contract has an ultimate completion date of September 14, 2023. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA,...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract has a potential value of $72,848.40 and a completion date of February 2, 2024. The order is for the pharmaceutical product XENPOZYME 20 MG VIALS. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that provides a wide range of pharmaceuticals and medical supplies to the federal government, particularly the Department...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The $145,696.80 award is for the delivery of XENPOZYME 20 MG VIALS, a pharmaceutical product, with a completion date of January 17, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $87,418.08, is for the delivery of XENPOZYME 20 MG VIALS, a specialized pharmaceutical product. The contract has an ultimate completion date of March 13, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain,...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business. The contract has a potential value of $109,272.60 and a completion date of March 7, 2024. DMS Pharmaceutical Group will provide XENPOZYME 20 MG VIALS to fulfill the agency's pharmaceutical supply needs. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract 4600082013 with DLA,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Xenpozyme 20 mg vials. The contract has a ceiling value of $87,418.08 and a completion date of November 21, 2024. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler based in Park Ridge, Illinois, that specializes in providing a range of pharmaceutical products and medical supplies to federal government agencies,...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB25FDK37
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of XENPOZYME 20 MG VIALS, a medical product, with a ceiling value of $87,418.08 and a period of performance through July 25, 2025. DMS Pharmaceutical Group has a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to issue delivery orders for a comprehensive range of pharmaceutical items supporting the medical supply needs of military health facilities worldwide. This positioning establishes DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.

Generated 10/2/25, 11:09 AM